Molecular and immunohistochemical effects of metformin in a rat model of type 2 diabetes mellitus

Ismail,Tamer  Ahmed; Soliman,Mohamed Mohamed; Nassan,Mohamed  Abdo

doi:10.3892/etm.2015.2354

May-2015 Volume 9 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2015 Volume 9 Issue 5

Full Size Image

Article

Molecular and immunohistochemical effects of metformin in a rat model of type 2 diabetes mellitus

Authors:
- Tamer Ahmed Ismail
- Mohamed Mohamed Soliman
- Mohamed Abdo Nassan
View Affiliations / Copyright

Affiliations: Medical Laboratory Department, Faculty of Applied Medical Sciences, Taif University, Taif, Mecca 21995, Saudi Arabia, Department of Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Sharqia 44519, Egypt
Pages: 1921-1930
|
Published online on: March 13, 2015

https://doi.org/10.3892/etm.2015.2354
Expand metrics +

Abstract

Type 2 diabetes mellitus (T2DM) is a serious health issue worldwide. The disease is characterized by insulin resistance (IR), which leads to dyslipidemia and alterations in the expression levels of a number of genes. Metformin is the standard treatment for T2DM; however, the exact mechanism underlying metformin regulation is not fully understood. The aim of the present study was to investigate the effects of metformin on serum lipid profiles and the expression levels of various genes that are associated with IR, as well as the histopathological changes in the liver and pancreas. A T2DM rat model was established by feeding the rats a high‑fat diet for 4 weeks, combined with a dose of streptozotocin (35 mg/kg body weight). Following the successful induction of T2DM, metformin was administered orally (400 mg/kg/day) for 4 weeks. The results indicated that metformin improved the symptoms of IR by normalizing the serum lipid profiles in the diabetic rats. Furthermore, metformin upregulated the expression of insulin receptors and genes associated with lipid metabolism, including acyl‑CoA oxidase, carnitine palmitoyl transferase‑1 and peroxisome proliferator activated receptor‑α. In addition, treatment with metformin downregulated the expression levels of fetuin‑A and retinol binding protein‑4 (RBP‑4), while normalizing the expression of perilipin that had been reduced in the T2DM rats. Metformin administration induced regenerative changes in the hepatocyte cytoplasm and parenchyma. In the pancreas, treatment with metformin was shown to induce positive signaling for insulin and the regeneration of pancreatic β cells. In summary, metformin treatment ameliorated a number of the harmful effects associated with T2DM via the modulation of the expression levels of fetuin‑A, RBP‑4, perilipin and various genes associated with lipid metabolism, resulting in regenerative changes in the liver and pancreatic cells.

View Figures

View References

1	Shaw JE, Sicree RA and Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
2	Roglic G and Unwin N: Mortality attributable to diabetes: Estimates for the year 2010. Diabetes Res Clin Pract. 87:15–19. 2010. View Article : Google Scholar : PubMed/NCBI
3	Stumvoll M, Goldstein BJ and van Haeften TW: Type 2 diabetes: Principles of pathogenesis and therapy. Lancet. 365:1333–1346. 2005. View Article : Google Scholar : PubMed/NCBI
4	Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad MF, Selby JV, Bergman R and Savage P: Insulin Resistance Atherosclerosis Study Investigators: Insulin sensitivity, insulinemia and coronary artery disease: the Insulin Resistance Atherosclerosis study. Diabetes Care. 27:781–787. 2004. View Article : Google Scholar : PubMed/NCBI
5	Myers MG Jr and Olson DP: Central nervous system control of metabolism. Nature. 491:357–363. 2012. View Article : Google Scholar : PubMed/NCBI
6	Reaven GM: The insulin resistance syndrome: Definition and dietary approaches to treatment. Annu Rev Nutr. 25:391–406. 2005. View Article : Google Scholar : PubMed/NCBI
7	Bouche C, Lopez X, Fleischman A, Cypess AM, O'Shea S, Stefanovski D, Bergman RN, Rogatsky E, Stein DT, Kahn CR, et al: Insulin enhances glucose-stimulated insulin secretion in healthy humans. Proc Natl Acad Sci USA. 107:4770–4775. 2010. View Article : Google Scholar : PubMed/NCBI
8	Rhodes CJ, White MF, Leahy JL and Kahn SE: Direct autocrine action of insulin on β-cells: Does it make physiological sense? Diabetes. 62:2157–2163. 2013. View Article : Google Scholar : PubMed/NCBI
9	Jung TW, Youn BS, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Kim BH, Baik SH and Choi KM: Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. Biochem Pharmacol. 86:960–969. 2013. View Article : Google Scholar : PubMed/NCBI
10	Mori K, Emoto M and Inaba M: Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov. 5:124–146. 2011. View Article : Google Scholar : PubMed/NCBI
11	Syed Ikmal SI, Zaman Huri H, Vethakkan SR and Wan Ahmad WA: Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease. Int J Endocrinol. 2013:6985672013.PubMed/NCBI
12	Sztalryd C and Kimmel AR: Perilipins: lipid droplet coat proteins adapted for tissue-specific energy storage and utilization and lipid cytoprotection. Biochimie. 96:96–101. 2014. View Article : Google Scholar : PubMed/NCBI
13	Zhou G, Myers R, Li Y, Chen Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
14	Woods YL, Petrie JR and Sutherland C: Dissecting insulin signaling pathways: Individualised therapeutic targets for diagnosis and treatment of insulin resistant states. Endocr Metab Immune Disord Drug Targets. 9:187–198. 2009. View Article : Google Scholar : PubMed/NCBI
15	Radziuk J, Zhang Z, Wiernsperger N and Pye S: Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes. 46:1406–1413. 1997. View Article : Google Scholar : PubMed/NCBI
16	Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B: American Diabetes Association, European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32:193–203. 2009. View Article : Google Scholar : PubMed/NCBI
17	Diamanti-Kandarakis E, Christakou CD, Kandaraki E and Economou FN: Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 162:193–212. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hundal RS and Inzucchi SE: Metformin: new understandings, new uses. Drugs. 63:1879–1894. 2003. View Article : Google Scholar : PubMed/NCBI
19	Srinivasan K, Viswanad B, Asrat L, Kaul CL and Ramarao P: Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacol Res. 52:313–320. 2005. View Article : Google Scholar : PubMed/NCBI
20	Bancroft JD and Gamble M: Theory and Practice of Histological Techniques6th. Churchill Livingstone Elsevier; Philadelphia, PA: pp. 126–127. 2008
21	Werner ED, Lee J, Hansen L, Yuan M and Shoelson SE: Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem. 279:35298–35305. 2004. View Article : Google Scholar : PubMed/NCBI
22	Elmadhun NY, Lassaletta AD, Chu LM and Sellke FW: Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome. J Thorac Cardiovasc Surg. 145:258–266. 2013. View Article : Google Scholar : PubMed/NCBI
23	Sykiotis GP and Papavassiliou AG: Serine phosphorylation of insulin receptor substrate-1: A novel target for the reversal of insulin resistance. Mol Endocrinol. 15:1864–1869. 2001. View Article : Google Scholar : PubMed/NCBI
24	Yogalakshmi B, Bhuvaneswari S, Sreeja S and Anuradha CV: Grape seed proanthocyanidins and metformin act by different mechanisms to promote insulin signaling in rats fed high calorie diet. J Cell Commun Signal. 8:13–22. 2014. View Article : Google Scholar : PubMed/NCBI
25	Grisouard J, Timper K, Radimerski TM, Frey DM, Peterli R, Kola B, Korbonits M, Herrmann P, Krähenbühl S, Zulewski H, et al: Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochem Pharmacol. 80:1736–1745. 2010. View Article : Google Scholar : PubMed/NCBI
26	Shepherd PR and Kahn BB: Glucose transporters and insulin action - implications for insulin resistance and diabetes mellitus. N Engl J Med. 341:248–257. 1999. View Article : Google Scholar : PubMed/NCBI
27	Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ and Kraegen EW: Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-γ activation. Diabetes. 50:411–417. 2001. View Article : Google Scholar : PubMed/NCBI
28	Escher P and Wahli W: Peroxisome proliferator-activated receptors: Insight into multiple cellular functions. Mutat Res. 448:121–138. 2000. View Article : Google Scholar : PubMed/NCBI
29	Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B and Auwerx J: PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:5336–5348. 1996.PubMed/NCBI
30	Kliewer SA, Umesono K, Noonan DJ, Heyman RA and Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 358:771–774. 1992. View Article : Google Scholar : PubMed/NCBI
31	Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T and Auwerx J: Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem. 270:19269–19276. 1995. View Article : Google Scholar : PubMed/NCBI
32	Louet JF, Chatelain F, Decaux JF, Park EA, Kohl C, Pineau T, Girard J and Pegorier JP: Long-chain fatty acids regulate liver carnitine palmitoyltransferase 1 gene (L-CPT I) expression through a peroxisome proliferator-activated receptor α (PPARα)-independent pathway. Biochem J. 354:189–197. 2001. View Article : Google Scholar : PubMed/NCBI
33	Hertz R, Bishara-Shieban J and Bar-Tana J: Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem. 270:13470–13475. 1995. View Article : Google Scholar : PubMed/NCBI
34	Chen WL, Wei HW, Chiu WZ, Kang CH, Lin TH, Hung CC, Chen MC, Shieh MS, Lee CC and Lee HM: Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens. Eur J Pharmacol. 671:107–112. 2011. View Article : Google Scholar : PubMed/NCBI
35	Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, et al: Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 51:2074–2081. 2002. View Article : Google Scholar : PubMed/NCBI
36	Schreurs M, Kuipers F and van der Leij FR: Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev. 11:380–388. 2010. View Article : Google Scholar : PubMed/NCBI
37	Clarke SD and Jump DB: Regulation of gene transcription by polyunsaturated fatty acids. Prog Lipid Res. 32:139–149. 1993. View Article : Google Scholar : PubMed/NCBI
38	Lingvay I, Raskin P and Szczepaniak LS: Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications. 21:137–142. 2007. View Article : Google Scholar : PubMed/NCBI
39	Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S and Girnun GD: Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila). 5:544–552. 2012. View Article : Google Scholar : PubMed/NCBI
40	Roden M: Mechanisms of disease: Hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2:335–348. 2006. View Article : Google Scholar : PubMed/NCBI
41	He J, Jiang H, Tansey JT, Tang C, Pu S and Xu G: Calyculin and okadaic acid promote perilipin phosphorylation and increase lipolysis in primary rat adipocytes. Biochim Biophys Acta. 1761:247–255. 2006. View Article : Google Scholar : PubMed/NCBI
42	Sztalryd C, Xu G, Dorward H, Tansey JT, Contreras JA, Kimmel AR and Londos C: Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. J Cell Biol. 161:1093–1103. 2003. View Article : Google Scholar : PubMed/NCBI
43	Ren T, He J, Jiang H, Zu L, Pu S, Guo X and Xu G: Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-α or isoproterenol. J Mol Endocrinol. 37:175–183. 2006. View Article : Google Scholar : PubMed/NCBI
44	Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L and Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 436:356–362. 2005. View Article : Google Scholar : PubMed/NCBI
45	Fischer CP, Perstrup LB, Berntsen A, Eskildsen P and Pedersen BK: Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol. 117:152–160. 2005. View Article : Google Scholar : PubMed/NCBI
46	Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK and Park KS: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 29:2457–2461. 2006. View Article : Google Scholar : PubMed/NCBI
47	Gavi S, Stuart LM, Kelly P, Melendez MM, Mynarcik DC, Gelato MC and McNurlan MA: Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab. 92:1886–1890. 2007. View Article : Google Scholar : PubMed/NCBI
48	Tajtáková M, Semanová Z, Ivancová G, Petrovicová J, Donicová V and Zemberová E: Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin. Vnitr Lek. 53:960–963. 2007.[(In Slovak)]. PubMed/NCBI
49	Fang P, Shi M, Yu M, Guo L, Bo P and Zhang Z: Endogenous peptides as risk markers to assess the development of insulin resistance. Peptides. 51:9–14. 2014. View Article : Google Scholar : PubMed/NCBI
50	Stoffers DA: The development of beta-cell mass: Recent progress and potential role of GLP-1. Horm Metab Res. 36:811–821. 2004. View Article : Google Scholar : PubMed/NCBI
51	Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA and Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:102–110. 2003. View Article : Google Scholar : PubMed/NCBI
52	Cozar-Castellano I, Fiaschi-Taesch N, Bigatel TA, Takane KK, Garcia-Ocaña A, Vasavada R and Stewart AF: Molecular control of cell cycle progression in the pancreatic beta-cell. Endocr Rev. 27:356–370. 2006. View Article : Google Scholar : PubMed/NCBI
53	Kahn SE, Hull RL and Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 444:840–846. 2006. View Article : Google Scholar : PubMed/NCBI
54	Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, Bugliani M, Boggi U, Vistoli F, Mosca F and Del Prato S: Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 89:5535–5541. 2004. View Article : Google Scholar : PubMed/NCBI
55	Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, Simard S and Marceau P: Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 135:48–58. 2004. View Article : Google Scholar : PubMed/NCBI
56	Kirpichnikov D, McFarlane SI and Sowers JR: Metformin: An update. Ann Intern Med. 137:25–33. 2002. View Article : Google Scholar : PubMed/NCBI